553Stage at diagnosis for six major cancers in China with comparison to the United States. (2nd September 2021)

• Record Type: Journal Article
• Authors: Ran, Xianhui; Zeng, Hongmei; Zhang, Siwei; An, Lan; Zheng, Rongshou; Wei, Wenqiang; He, Jie
• Is Part Of: International journal of epidemiology. Volume 50(2021)Supplement 1
• Publication Date: 2021-09-02
• Subjects: Epidemiology -- Periodicals; 614.4
• DOI: 10.1093/ije/dyab168.558
• Languages: English
• ISSNs: 0300-5771

Abstract

Abstract: Background: To explore the distribution and factors associated with cancer stage at diagnosis, we conducted a multi-center hospital-based study in China. Methods: 38 hospitals were selected to set up the Chinese cancer clinical database. Detailed stage information was collected from clinical records and focus on cancers of the lung, stomach, colon-rectum, liver, female breast, and esophagus diagnosed during 2016-2017. We compared the stage distribution with the US by data from Surveillance, Epidemiology, and End Results database during the same period. Results: Overall 69632 first diagnosed cancer cases were analyzed. The proportion of cancer patients in stage I varies by cancer site, with highest in breast (28%) and lowest in liver (13%). The proportion of cancer cases at stage I was generally higher in women (OR:1.7, 95%CI:1.6-1.8), in young (<65 years) (OR:1.2, 1.1-1.2) and in subjects having Chinese Urban Insurances (OR:1.9, 1. 8-2.0). Except for esophageal cancer, the other five major cancers in China had more advanced stage than in the US. Conclusions: Socio-demographic inequalities exist in stage at diagnosis for major cancer cases in China. Early detection interventions are especially needed to be targeted on patients with higher risk of advance disease diagnosis. Key messages: Multi-center hospital-based study on cancer stage distribution in China shows that women, young, and those with Chinese Urban Insurance were more likely to be diagnosed with early stage. Stage distribution in China was generally more advanced compared with cancer patients in the US.